JUN 20, 2018 09:00 AM PDT

Identifying Driver Alterations and Therapeutic Options in Cancer

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Head of Knowledge Systems, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
    Biography
      Nikolaus Schultz leads the development of the cBioPortal for Cancer Genomics, a popular resource for the visualization and analysis of large-scale cancer genomics data sets. His research focuses on identifying the genomic alterations that underlie different types of cancer. He is involved in several projects of The Cancer Genome Atlas (TCGA) and is an investigator in the Stand Up To Cancer (SU2C) Prostate Cancer Dream Team.

      Dr. Schultz is an Associate Attending Computational Oncologist in the Department of Epidemiology and Biostatistics and an affiliate member of the Human Oncology and Pathogenesis Program. He is the Head of Knowledge Systems in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology.

    Abstract:

    With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for clinical support tools that aid clinicians in their decision making. To this end, we are developing tools for the visualization and interpretation of genomic variants in the context of clinical annotation. 

    To this end, we have developed OncoKB, a precision oncology knowledge base that annotates the effects and treatment implications of somatic mutations in cancer. OncoKB annotations are available for research use via oncokb.org, and the database is used to annotate the sequencing reports of of tumor samples from patients at Memorial Sloan Kettering Cancer Center. 

    We are also co-developers of the cBioPortal for Cancer Genomics. The cBioPortal is an open source software tool that provides intuitive visualization and analysis of cancer genomics data, allowing cross-cohort analyses but also the viewing and interpretation of individual tumor samples. The public site at cbioportal.org provides access to published sequencing data from more than 25,000 tumor samples, and private instances of cBioPortal are installed at multiple academic research centers, in hospitals, and pharmaceutical companies. Annotations from OncoKB as well as other sources, such as COSMIC, CIViC, and cancerhotspots.org, are integrated into cBioPortal to facilitate the interpretation of variants in cancer cohorts and individual patient samples.

    This presentation will summarize the challenges of precision oncology and cancer genomics research and will present how OncoKB and the cBioPortal for Cancer Genomics can be used to overcome some of these challenges.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...
    Show Resources